You are here: Industry Insights > RCC

News List

Aravive Receives IND Clearance for AVB-500 Trial for Clear Cell Renal Cell Carcinoma americanpharmaceuticalreview
January 17, 2020
Aravive announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application for investigation of the company’s lead candidate, AVB-500, for the treatment of clear cell renal cell carcinoma (ccRCC
BMS’ Opdivo plus Yervoy for RCC to be available through NHS Scotland pharmaceutical-technology
June 13, 2019
Scotland’s healthcare pricing regulator the Scottish Medicines Consortium (SMC) has decided to fund Bristol-Myers Squibb (BMS)’s Opdivo (nivolumab) plus Yervoy (ipilimumab) for use in NHS Scotland for renal cell carcinoma (RCC) patients ...
Keytruda combo wins FDA approval for RCC pharmatimes
April 25, 2019
The US Food and Drug Administration (FDA) has approved MSD’s Keytruda (pembrolizumab), in combination with Inlyta(axitinib), as first-line treatment for patients with advanced renal cell carcinoma (RCC).
NICE recommends BMS’ Opdivo-Yervoy combination for RCC pharmaceutical-technology
April 09, 2019
Bristol-Myers Squibb (BMS) has announced that the National Institute of Health and Care Excellence (NICE) has recommends Opdivo (nivolumab) and...
Merck Group and Pfizer announce positive results for combo therapy for RCC pharmaceutical-technology
February 19, 2019
Pfizer and German-based Merck Group have published promising interim results from their Phase III JAVELIN Renal 101 trial evaluating the efficacy and safety of ....
Roche withdraws Tecentriq combo application in first-line renal cell carcinoma pharmafile
November 20, 2018
The EMA has revealed that Roche has chosen to withdraw its marketing application for immunotherapy Tecentriq (atezolizumab) in combination with Genentech’s Avastin
Pfizer pulls plug on Inlyta trial pharmatimes
July 17, 2018
Pfizer is terminating a late-stage trial assessing Inlyta in patients at risk of kidney cancer recurrence after an interim analysis showed that it was highly unlikely the drug would offer any benefit in this setting.
EU OKs first-line use of Ipsen’s Cabometyx pharmatimes
July 12, 2018
The European Commission has approved Ipsen/Exelixis’ Cabometyx for the first-line treatment of adults with advanced renal cell carcinoma (RCC).
European Commission licences EUSA’s advanced RCC treatment fotivda pharmaceufical-technology
September 01, 2017
Jazz Pharmaceuticals subsidiary EUSA Pharma’s fotivda (tivozanib) has been licensed by the European Commission (EC) for first-line treatment of adult patients with advanced renal cell carcinoma (RCC).

Previous page 1 2 Next page